Mirum Pharmaceuticals, Inc. (MIRM) Stock Price & Analysis
Mirum Pharmaceuticals, Inc. (MIRM) closed at USD 83.1 on Thursday, October 22, 2026, down 0.41% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 83.44; the Oct 22, 2026 session ranged USD 82.58–84.86 on volume of 420,911 shares. Market capitalization is $5.40B, with a 52-week range of USD 63.23–130 (NGM). Source: Nexqual, retrieved October 23, 2026 at 09:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MIRM.md
Key facts (MIRM)
- Last four reported quarters (through Jun 30, 2026): revenue $618M, net income -$860M (-139.2% margin), free cash flow -$229M (SEC filings).
- 1 of 80 tracked superinvestors hold MIRM (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Total return with dividends: 1Y +19.7% vs S&P 500 +14.9%; 5Y +446.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD -0.42, revenue estimate $178M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MIRM)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $19.1M | $77.1M | $186M | $337M | $521M | $618M |
| Operating income | -$173M | -$131M | -$109M | -$87.6M | -$22.1M | -$834M |
| Net income | -$84.0M | -$136M | -$163M | -$87.9M | -$23.4M | -$860M |
| EPS (diluted) | -$2.77 | -$4.02 | -$4.00 | -$1.85 | -$0.47 | — |
| Free cash flow | -$133M | -$120M | -$71.1M | $9.3M | $54.9M | -$229M |
| Operating margin | -906.1% | -170.3% | -58.6% | -26.0% | -4.2% | -134.9% |
| Net margin | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% | -139.2% |
| Revenue growth | — | +302.7% | +141.8% | +80.8% | +54.7% | — |
| Cash + short-term investments | $157M | $152M | $286M | $280M | $383M | — |
| Total debt | — | $0K | $306M | $308M | $310M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (MIRM)
P/S 8.7x · EV/Sales 9.2x · FCF yield -4.24% · Earnings yield -15.94% · Net debt $312M · EV $5.71B
Superinvestors (SEC 13F-HR, Q2 2026) (MIRM)
1 of 80 tracked investors hold MIRM. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Polen Capital | Polen Capital Management | 0.02% | $2.4M | Added +1.8% |
Analysts (MIRM)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | TD Cowen | Target raised | Buy | $140 → $145 |
| 2026-10-15 | Stifel | Target raised | Buy | $136 → $156 |
| 2026-10-13 | Evercore ISI Group | Target raised | Outperform | $135 → $146 |
| 2026-10-13 | Morgan Stanley | Target raised | Overweight | $137 → $152 |
| 2026-10-12 | Citigroup | Target raised | Buy | $160 → $184 |
| 2026-10-12 | HC Wainwright & Co. | Target raised | Buy | $195 → $200 |
| 2026-10-08 | RBC Capital | Target raised | Outperform | $135 → $155 |
| 2026-09-29 | Citigroup | Target raised | Buy | $145 → $160 |
| 2026-09-29 | Baird | Target raised | Outperform | $123 → $130 |
| 2026-09-28 | HC Wainwright & Co. | Target raised | Buy | $140 → $195 |
| 2026-08-27 | Citizens | Reiterated | Market Outperform | $137 |
| 2026-08-06 | TD Cowen | Target lowered | Buy | $145 → $140 |
Total return (dividends reinvested) (MIRM)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +19.7% | +446.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +19.8% | +40.3% |
| Volatility (annualized) | 47.8% | 44.8% |
| Max drawdown | -38.4% (Jul 2026→Oct 2026) | -38.3% (Aug 2022→Dec 2022) |
MIRM revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product sales, net | $176.2M | 100.0% | +37.9% |
| — Livmarli (part of Product sales, net) | $128.7M | 73.0% | +46.0% |
| — Bile Acid Medicines (part of Product sales, net) | $47.5M | 27.0% | +19.9% |
| Total revenue | $176.2M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
MIRM suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | General | “General business and economic conditions that could affect our business, financial condition or results of operations include fluctuations in economic growth, inflation and interest rates, debt and equity capital markets, liquidity of the global financial markets, the availability and cost of credit, investor and consumer confidence, and the strength of the economies in which we, our manufacturers, suppliers and o…” |
| Partner | Shire International | “We will solely own all inventions and discoveries arising out of activities conducted by us under the Shire License Agreement.” |
| Partner | Pfizer (PFE) | “Pursuant to the Shire License Agreement, Shire assigned, transferred and conveyed all of its right, title and interest in and to the license agreement, as amended ("Satiogen Agreement"), with Satiogen Pharmaceuticals, Inc. ("Satiogen"), now a wholly owned Mirum entity, under which we obtained an exclusive, worldwide license to certain patents and know-how controlled by Satiogen related to ASBTis ("ASBTi Technology…” |
| Partner | Lonza | “Manufacturing and License Agreement with Lonza Ltd.” |
| Partner | Travere Therapeutics, Inc. (TVTX) | “Asset Purchase Agreement with Travere Therapeutics, Inc.” |
| Partner | Sanofi-Aventis Deutschland | “Through the Shire License Agreement, we were assigned the rights to the license agreement, as amended ("Sanofi Agreement"), with Sanofi-Aventis Deutschland GmbH ("Sanofi"), under which we obtained an exclusive, worldwide license to certain patents and know-how controlled by Sanofi related to volixibat ("Sanofi Technology").” |
| Partner | Enthorin Therapeutics | “On October 22, 2024, we entered into a license agreement (the "MRM-3379 License") with Enthorin Therapeutics, LLC and Dart Neuroscience LLC (collectively "Enthorin").” |
| Partner | Dart Neuroscience | “On October 22, 2024, we entered into a license agreement (the "MRM-3379 License") with Enthorin Therapeutics, LLC and Dart Neuroscience LLC (collectively "Enthorin").” |
| Partner | Satiogen Pharmaceuticals | “We have our license agreement with Shire, Satiogen and Pfizer for our intellectual property rights covering maralixibat.” |
Quoted from the company's 10-K filed Feb 25, 2026.
MIRM company outlook (results filed Aug 5, 2026)
- “Guidance to $680 Million to $700 Million • Second quarter 2026 global net product sales of $176.2 million. • Second quarter 2026 LIVMARLI ® net product sales were $128.7 million, representing 46% growth over second quarter 2025 net product sales. • Second quarter 2026 Bile Acid Medicines net product sales were $47.5 million, representing 20% growth over second quarter 2025 net product sales.”
Analysts expect $177.8M for the current quarter, 74.2% below the midpoint of the company's guidance ($690.0M).
Quoted word-for-word from the SEC 8-K results press release.
MIRM analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.41 | $-0.69 | -39.5% | $177.8M | 2 |
| Next quarter (ends Dec 2026) | $-0.44 | $-0.46 | -3.8% | $183.3M | 1 |
| Current fiscal year (ends Dec 2026) | $-15.23 | $-14.24 | +7.0% | $698.1M | 1 |
| Next fiscal year (ends Dec 2027) | $-0.70 | $-0.19 | +275.0% | $819.6M | 2 |
Key Statistics (as of October 23, 2026 at 09:21 UTC)
| Price | USD 83.1 |
|---|---|
| Change | ▼ 0.41% (down) |
| Previous Close | USD 83.44 |
| Open | USD 83.26 |
| Day Range | USD 82.58 – 84.86 |
| 52-Week Range | USD 63.23 – 130 |
| Volume | 420,911 shares |
| Market Cap | $5.40B |
| Exchange | NGM |
Technical Analysis (MIRM)
Nexqual's technical model rates MIRM "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:21 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.08 (neutral) |
| vs SMA50 | Below (USD 91.79) |
| MACD | -2.75 (negative) |
Earnings (MIRM)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -0.42 |
| Revenue Estimate | $177.84M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.8 vs est -0.75 ▼ miss |
| 2026-03-31 | USD -1.09 vs est -0.36 ▼ miss |
| 2025-12-31 | USD -0.12 vs est 0.06 ▼ miss |
| 2025-09-30 | USD 0.05 vs est -0.16 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Financials & Fundamentals (MIRM)
| Total Revenue | $618.07M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +37.90% |
| Gross Margin | +81.73% |
| Operating Margin | -14.81% |
| Profit Margin | -139.18% |
| ROE | -702.97% |
| Current Ratio | 2.86 |
| Total Cash | $438.29M |
| Total Debt | $762.95M |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Ownership (MIRM)
| Insider Ownership | +1.31% |
|---|---|
| Institutional Ownership | +111.82% |
| Shares Outstanding | 64.93M |
| Float | 56.40M |
| Short % of Float | +13.85% |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Leadership (MIRM)
Mirum Pharmaceuticals, Inc. is led by Christopher Peetz, CEO & Director, per Nexqual as of October 23, 2026 at 09:21 UTC.
| CEO & Director | Christopher Peetz |
|---|---|
| COO & President | Peter Radovich |
| Chief Financial Officer | Eric H. Bjerkholt M.B.A., M.S. |
| Senior Vice President, Strategic Finance & Investor Relations | Andrew McKibben |
| Senior Director of Global Corporate Communications | Meredith Kiernan |
Major Backers & Investors (MIRM)
Notable institutional backers of Mirum Pharmaceuticals, Inc. include Frazier Life Sciences Management, L.P. , Jupiter Topco LLC, FMR, LLC, according to Nexqual as of October 23, 2026 at 09:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 11.83% |
| Jupiter Topco LLC | 9.1% |
| FMR, LLC | 5.65% |
| Price (T.Rowe) Associates Inc | 4.09% |
| William Blair Investment Management, LLC | 2.16% |
| Fidelity | 2.07% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.13% |
| BlackRock | 6.76% |
| State Street | 3.34% |
| Geode Capital | 2.15% |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
From Mirum Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Food and Drug Administration ("FDA") approved Cholbam in March 2015 as the first FDA-approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder ("PBD-ZSD").
- We submitted a New Drug Application ("NDA") for chenodiol for the treatment of CTX in 2024 and received FDA approval for the treatment of adults with CTX in February 2025.
- Cholbam for the treatment of bile acid synthesis disorders and peroxisomal disorders, including PBD-ZSD The FDA approved Cholbam (cholic acid capsules) in March 2015, as the first FDA-approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including PBD-ZSD.
- Our success also depends in part on our ability to operate without infringing the proprietary rights of others, and in part, on our ability to prevent others from infringing our proprietary rights.
Partnerships
- In conjunction with the manufacture and commercialization of brelovitug, Bluejay entered into a master services agreement with Lonza Ltd. ("Lonza") in October 2021 and a license agreement with Lonza Sales AG in December 2022 (the "Lonza License Agreement").
- In August 2023, we completed the acquisition of assets of Travere Therapeutics, Inc. ("Travere") that are primarily related to the development, manufacture (including synthesis, formulation, finishing or packaging) and commercialization of chenodiol and Cholbam (also known as Kolbam) (and together with chenodiol, the "Bile Acid Medicines") pursuant to an asset purchase agreement dated July 16, 2023 (such acquisition, the "Bile Acid Portfolio Acquisition").
Legal & Regulatory Risks (Item 1A, quoted)
- We may face product liability exposure, and if claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate.
- Our approved medicines and our product candidates are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. We may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with any product.
- We are subject to various FDA and EU post-marketing requirements across our approved medicines, including the conduct and submission of registry studies and the FDA's and EU's prohibition against marketing medicines in uses that are not approved. These and similar requirements could be imposed by the FDA, European Commission or comparable foreign regulatory authorities for any approved product.
- Our business depends, in part, on the success of our product candidates, each of which requires significant clinical testing before we can seek regulatory approval and potentially launch commercial sales.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt